Thrivent Financial for Lutherans Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT

Thrivent Financial for Lutherans boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 204.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,493 shares of the biotechnology company’s stock after buying an additional 47,353 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.07% of Sarepta Therapeutics worth $1,358,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Federated Hermes Inc. raised its position in shares of Sarepta Therapeutics by 347.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock worth $22,370,000 after acquiring an additional 1,016,069 shares in the last quarter. Norges Bank bought a new stake in Sarepta Therapeutics during the second quarter valued at about $15,619,000. Y Intercept Hong Kong Ltd grew its stake in Sarepta Therapeutics by 1,736.5% in the second quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock valued at $14,880,000 after purchasing an additional 822,799 shares during the last quarter. 683 Capital Management LLC raised its holdings in Sarepta Therapeutics by 309.1% in the second quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock worth $11,542,000 after purchasing an additional 510,000 shares in the last quarter. Finally, Opaleye Management Inc. purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at about $8,550,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 2.2%

NASDAQ SRPT opened at $17.79 on Friday. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $111.21. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79. The company has a market capitalization of $1.86 billion, a PE ratio of -5.91, a P/E/G ratio of 0.44 and a beta of 0.39. The company has a fifty day moving average of $21.11 and a 200 day moving average of $20.13.

Insider Activity

In other news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Wells Fargo & Company cut their price objective on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Wedbush increased their price objective on Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday, January 27th. Barclays initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 price target for the company. Finally, Wall Street Zen downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $33.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.